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Previous studies in our laboratory have shown that albendazole is effective against Giardia spp. in vitro and
in vivo, prompting an investigation ofthe effects ofseveral related benzimidazoles (BZs) on the viability ofthis
protozoan parasite. A range of BZs was tested, and their effects were compared with those of a number of
microtubule inhibitors. The effects produced by the two types of drugs were markedly similar, namely,
trophozoite detachment and distortion of morphology and general structure, indicating a potential antimicro-
tubule mode of action for BZs. Mebendazole, albendazole, and fenbendazole proved to be among the most
effective BZs tested, exhibiting apparent irreversibility. Nocodazole, oxfendazole, and albendazole sulfoxide,
among others, produced transient inhibitions only. Further studies are required to evaluate all available BZs
and other antigiardial agents to ensure the development of the most effective and safest antigiardial agent
possible.
Giardia duodenalis is one ofthe most commonly identified
intestinal pathogens in the world (15). Although it has a
global distribution (23), G. duodenalis is especially prevalent
in developing countries and among disadvantaged groups,
such as Australian Aborigines. Young children are particu-
larly at risk since high levels of G. duodenalis can cause
acute or chronic diarrhea, protein-calorie malnutrition, and
failure to thrive (15).
Efforts to control giardiasis by using therapeutic agents
have been based on a number of compounds, including
quinacrine, several nitroimidazole derivatives (metroni-
dazole and tinidazole), and a nitrofuran, furazolidone. Al-
though therapy with these drugs is usually effective, there
are still limitations to their use, because they all exhibit
undesirable side effects and, in the case of metronidazole,
may be carcinogenic (30). Treatment failures can sometimes
occur, requiring repeated courses of therapy (9). This re-
peated exposure to potentially dangerous drugs, particularly
in communities in which reinfection, and thus frequent
therapy, is common, is an area of grave concern. There is
also evidence ofvariable drug susceptibilities among Giardia
isolates (10, 11) and even within laboratory-derived clonal
lines of G. duodenalis (3).
The search for alternative antigiardial agents led to a
reevaluation of the benzimidazoles (BZs) as antiprotozoan
agents (22, 27, 28). The BZs have been successfully used for
many years as anthelmintics (31) and are thought to target
tubulin (17), a major component of Giardia cytoskeletal
structures. Alternative theories include alteration of the
bioenergetics of Giardia spp. by BZs, which act as lipid-
soluble proton ionophores (20). Previous studies in our
laboratory have shown that the BZ albendazole is a more
effective antigiardial agent in vitro than either metronidazole
or tinidazole (22). Other investigators (6) have reported the
superior antigiardial efficacy of mebendazole over metroni-
dazole. These findings, together with confirmation of the
efficacy of albendazole in an in vivo study that used mouse
and rat models (26, 27), have prompted a more extensive
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investigation into the effect ofseveral related BZs and also a
number of other microtubule inhibitors on the viability of G.
duodenalis in vitro.
MATERIALS AND METHODS
Organisms and cultures. Trophozoites of the G. duodena-
lis isolate PlclO (a clone ofthe Portland isolate P1 developed
in our laboratory) were cultured at 37°C in modified BI-S-33
medium containing 10% newborn bovine serumbut no added
antibiotics (21).
Chemotherapeutic agents. Albendazole and albendazole
sulfoxide were supplied by SmithKline Beecham. Nocoda-
zole, fenbendazole, oxfendazole, cis- and trans-tubulozole,
2-propionamido-5-benzoyl benzimidazole, thiabendazole,
mebendazole, ,B-lumicolchicine, colchicine, griseofulvin,
vinblastine, and podophyllotoxin were gifts from E. Lacey,
McMaster Laboratory, Commonwealth Scientific and Indus-
trial Research Organisation, Sydney, Australia. Solutions of
BZs and tubulin inhibitors were prepared fresh in dimethyl
sulfoxide. The final dimethyl sulfoxide concentration in the
culture tubes was always <0.5%.
Adherence inhibition assays. The susceptibility of G. duo-
denalis in vitro to the indicated drugs was determined as
described previously (22), with one modification. Briefly,
trophozoites were exposed to the drug for either 4 or 24 h,
after which the culture medium was replaced with drug-free
medium. The centrifugation step to pellet trophozoites prior
to changing the medium was omitted because healthy tro-
phozoites attach to the culture vessel wall and the majority
ofunattached trophozoites form a pellet at the bottom ofthe
tube and are not removed when the medium is replaced.
Controls containing equivalent concentrations of dimethyl
sulfoxide were treated similarly. All experiments were per-
formed in duplicate. The main criterion for determining drug
susceptibilitywas trophozoite attachment to the culture tube
walls, since attachment is highly characteristic ofthis organ-
ism and is an important indicator ofviability (6, 19). Indeed,
it has been suggested that adherence inhibition may be a
more efficient mechanism for host resistance to Giardia spp.
than killing and that the adherence mechanism of Giardia
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TABLE 1. Comparison of IB50s for the inhibition of
[3H]mebendazole binding by preincubation of inhibitor and then
the addition of [3H]mebendazole to H. contortus L3 crude tubulin
extracts and IC50s for BZ efficacy against Giardia spp. in vitro
Drug MBZ IB50 (,M) for IC50(>M) for Giardia spp.
H. contortusa after 24 h of exposure
Nocodazole 0.12 0.07
Mebendazole 0.19 0.19
Albendazole 0.21 0.25
Fenbendazole 0.18 0.30
Oxfendazole 1.30 4.20
Albendazole sulfoxide 2.30 3.15
a [3H]mebendazole was added to H. contortus L3 crude tubulin extracts as
described previously (17).
isolates is a feasible and more efficient target for therapy (5).
Morphology and motility were also taken into account. A
previously described semiquantitative method (22) was used
to determine trophozoite adherence over 48 h. Dose-re-
sponse curves were constructed for all drugs, and the
concentration that caused a 50% reduction in adherence
compared with that in controls (IC50) was calculated. Cul-
tures were assessed at 4, 24, and 48 h.
Selection for albendazole resistance. Experimental selec-
tion of a drug-resistant line of G. duodenalis was attempted
by growing isolate PlclO in medium containing a range of
sublethal albendazole concentrations (0.16, 0.32, and 0.64
,uM). After 24 and 72 h of incubation, unattached cells were
discarded and fresh medium was added. Trophozoites were
allowed to recover for 24 h before reincubation with the
drug. The isolate was maintained in this way for over 6
months.
RESULTS
Inhibition of adherence in vitro. In all cases, trophozoites
exposed to drugs for either 4 or 24 h were assessed for
trophozoite adherence at 4, 24, and 48 h. IC50s were calcu-
lated at 48 h and were compared to previously published
concentrations that cause a 50% inhibition of binding com-
pared with that in controls (IB50s) for the binding of labeled
mebendazole to nematode tubulin (17) (Table 1). Of the
drugs tested, nocodazole, mebendazole, albendazole, and
fenbendazole were the most potent, with IC50s for a 24-h
exposure of0.07, 0.19, 0.25, and 0.3 ,uM, respectively. IC50s
for a 4-h exposure were 2.56, 2.7, 3.7, and 4 ,uM, respec-
tively (Fig. 1). Oxfendazole had good potency against Giar-
dia isolates for 24 h of exposure, with an IC50 of 4.2 ,uM.
However, it was not effective with a 4-h exposure, having an
IC50 of 85 ,uM. Albendazole sulfoxide, a metabolite of
albendazole, was effective against the Giardia isolates only
at high doses, especially after 4 h ofexposure, having an IC50
of 63.3 ,uM. Thiabendazole also had low potency against
Giardia isolates, requiring high doses to be effective in vitro,
with IC50s of 30.4 ,uM for a 24-h exposure and 203.2 ,uM for
a 4-h exposure. The compound 2-propionamido-5-benzoyl
benzimidazole did not exhibit any antigiardial effects at 24 h
of exposure at the highest concentration tested (20 ,uM).
With mebendazole, albendazole, and fenbendazole, inhibi-
tion of Giardia growth in vitro was maintained beyond 72 to
96 h. Drug-affected cells became totally distorted in shape
and failed to complete cellular division (22). Transmission
electron microscopy of drug-affected cells also confirmed
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FIG. 1. In vitro efficacies of nocodazole, mebendazole, albenda-
zole, and fenbendazole against Giardia isolates after 4 h (A) and 24
h (B) of exposure. Values are taken from the assessment at 48 h.
this (24). All other BZs failed to maintain their inhibition to
various degrees beyond 48 h.
Of the microtubule inhibitors tested, vinblastine exhibited
the greatest efficacy against Giardia isolates in vitro, with an
IC50 of 0.7 ,uM for a 24-h exposure, but did not exhibit
efficacy for 4 h of exposure at the concentrations tested (to
10 ,uM). Podophyllotoxin, griseofulvin, and colchicine had
IC50s of 4.2, 29.2, and 38.1 ,uM, respectively, for a 24-h
exposure but, again, were not effective at the 4-h exposure at
the concentrations tested (10, 50, and 50 ,uM, respectively).
cis- and trans-tubulozole and ,-lumicolchicine were not
effective at the concentrations tested (2.56, 10.24, and 50
,uM, respectively). Vinblastine alone maintained its inhibi-
tion beyond 72 h.
Failure to demonstrate in vitro resistance to albendazole.
Efforts to select for albendazole-resistant Giardia isolates in
vitro were unsuccessful. Resistant cells were defined as
being viable and also attaching to the culture vessel wall.
Drug-free passages were continued because incubation of
trophozoites with the drug for 96 h or more resulted in
complete inhibition of Giardia growth, even when the drug
was used at low concentrations (0.08 ,uM).
DISCUSSION
The BZs are broad-spectrum drugs which have been used
for many years in the treatment of helminthiasis in animals
and humans (4). It is only relatively recently that their in
vitro antigiardial activities have been evaluated (6, 22, 28). In
the present study we assessed several related BZs and a
number of microtubule inhibitors for their in vitro efficacies
against Giardia viability.
Of the BZs tested, nocodazole was the most potent.
Nocodazole, however, did not maintain its antigiardial ac-
tivitybeyond 48 h, which is in sharp contrast to the activities
ofmebendazole, albendazole, and fenbendazole, with which
VOL. 37, 1993ANTIMICROB. AGENTS CHEMOTHER.
inhibition was maintained. In addition, nocodazole is not a
widely used anthelmintic agent, and information on its
potential toxicity and side effects is limited. Nocodazole is
also a potent inhibitor of mammalian tubulin (13), which
would indicate potential toxicity to humans.
Mebendazole, albendazole, and fenbendazole are com-
monly used drugs with broad spectra of activity against a
range of different parasites which includes gastrointestinal
nematodes, lung and other tissue nematodes, cestodes, and
trematodes (16). The toxicities of these agents are low, and
they cause few side effects, with only slight side effects
reported in some individuals treated with these drugs. Al-
bendazole, mebendazole, and oxfendazole are known to
produce embryotoxicity and teratogenesis in laboratory an-
imals, however, and should not be given to pregnant women
(4). Flubendazole (a fluorine analog of mebendazole) and
fenbendazole, however, have not been shown to exhibit
these effects. In human clinical practice, only albendazole,
mebendazole, thiabendazole, and flubendazole are currently
in use as anthelmintic agents (14). Albendazole sulfoxide
was considerably less effective than albendazole, and the
apparent reversibility of its action limits its potential useful-
ness as an antigiardial agent. Thiabendazole had very low
potency against Giardia spp., and because side effects are
sometimes experienced with this drug (4), it is not consid-
ered to be a suitable candidate for antigiardial chemother-
apy.
The microtubule inhibitor vinblastine exhibited good po-
tency against Giardia isolates in vitro with a 24-h exposure
and also appeared to act irreversibly, in contrast to the
reversible action of podophyllotoxin, griseofulvin, and
colchicine. The toxicities of these drugs, however, render
them unsuitable as antigiardial agents (18).
There is increasing evidence, however, that the primary
mode of action of BZs against helminths is via inhibition of
tubulin (18). Additional evidence for this is that BZ resis-
tance in Haemonchus contortus may be due to point muta-
tions that cause structural changes in 3-tubulin, which in
turn interferes with BZ binding. Also, the deletion of a
BZ-susceptible ,-tubulin gene in Caenorhabditis elegans
was found to confer BZ resistance (29). It is therefore
important to determine whether BZs exert their effects
against Giardia spp. as tubulin antagonists, similar to the
mechanism in nematodes (18), or whether efficacy against
Giardia spp. is related to some unique aspect of the drug-
parasite interaction. In support of a microtubule antagonist
antigiardial mode of action for the BZs, a good correlation
exists between the inhibition oflabeled mebendazole binding
to nematode tubulin (17) and efficacy against Giardia spp. in
vitro (r = 0.856, n = 6), suggesting a similar mode of action
of the BZs in the two types of parasites. It is also possible
however, that these drugs bind to Giardia-specific proteins
called giardins (25), which are found only in the ventral disc.
Presumably, the giardins play a major role in the functioning
of the ventral disc and are good candidates for specific
chemotherapeutic attack. It is interesting that BZ-affected
Giardia isolates retain flagellar activity; flagellae rely on
tubulin and not giardin for their integrity (6, 22).
Previous investigators (6) have also shown that BZs are
effective against Giardia spp., noting that "treatment caused
cells to detach" and that "treatment induced gross morpho-
logic changes not seen with any other drug." Given the
predominant role that microtubules play in attachment and
also cell structure (7), this is further supportive evidence that
microtubule antagonism is indeed the primary antigiardial
mode of action of BZs. The efficacies of the tubulin inhibi-
tors tested against Giardia spp. also tend to support this
idea, because the effects produced by the tubulin inhibitors
werevery similar to those producedbythe BZs. Vinblastine,
podophyllotoxin, griseofulvin, and colchicine treatments all
resulted in trophozoite detachment and drastic changes in
the general morphologies of the trophozoites. Interestingly,
2-propionamido-5-benzoyl benzimidazole did not inhibit Gi-
ardia adherence at all, and this compound was specifically
constructed as a noninhibitor of tubulin (17), lending further
support to this theory. Previous investigators (6, 17) have
reported that BZ binding appears to be reversible. Once BZ
is bound, however, it may produce a cascade of direct and
indirect biochemical and physiological changes (17, 18),
resulting in the irreversible effects that we observed, irre-
spective of whether the drug is still bound or not. The
mechanism of antigiardial activity of BZs is being investi-
gated in our laboratory in order to provide a basis for the
development of the most effective drug and dosing strate-
gies.
Mebendazole, albendazole, and fenbendazole are poten-
tially some ofthe most useful antigiardial agents, having high
in vitro potencies against Giardia spp., an effect which
appears to be irreversible. Although only one Giardia isolate
was used in the present study, previous unpublished studies
in our laboratory have shown that albendazole has similar
potencies against 10 different Giardia isolates ofboth human
and animal origin. Both albendazole and mebendazole are
relatively insoluble, and a reasonable proportion of the
administered dose remains in the gastrointestinal tract (12),
thus optimizing contact with Giardia isolates. In vivo studies
in mice (26, 27) support the findings that BZs are effective
antigiardial agents; similarly, in rats, three doses ofless than
10 mg of albendazole per kg ofbodyweight were completely
effective in clearing the small intestine of trophozoites (27).
Recent studies have suggested that albendazole (33) and
mebendazole (1, 2) have clinical efficacy against giardiasis.
The claims for mebendazole have been disputed, however
(8), and more systematic clinical trials are necessary to
establish its clinical efficacy. Our lack of success in devel-
oping albendazole-resistant Giardia isolates in vitro can be
seen as encouraging since a problem with the BZs when used
as anthelmintic agents in domestic animals has been the
development of resistance to the drugs (32).
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